Impact of Centralisation on Abdominal Aortic Aneurysm Repair Outcomes: Early Experience in Catalonia.


Journal

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery
ISSN: 1532-2165
Titre abrégé: Eur J Vasc Endovasc Surg
Pays: England
ID NLM: 9512728

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 15 06 2019
revised: 06 02 2020
accepted: 09 03 2020
pubmed: 22 4 2020
medline: 21 10 2020
entrez: 22 4 2020
Statut: ppublish

Résumé

Several studies have revealed high volume centres have better outcomes in the treatment of abdominal aortic aneurysms (AAAs), thus supporting centralisation of this procedure into selected centres based on volume. To date however, the real benefit of centralisation of this pathology has not been well demonstrated. The aim of this study was to analyse the impact of centralisation in to high volume centres (defined as those performing more than 30 cases per year) on AAA treatment outcomes carried out in Catalonia (Spain). Data were collected from official national registries (HDMBD) for AAA treated by endovascular aneurysm repair (EVAR) or open repair (OR) over a nine year period. Two time periods were selected for comparison: before centralisation (2009-2014) and after complete centralisation (2015-2017). The primary objective was to determine short term mortality (in hospital and 30 day mortality) and length of stay (LOS) after intact AAA (iAAA) and ruptured AAA (rAAA) repair, before and after centralisation. Uni- and multivariable analyses were performed in order to identify independent outcomes predictors. A total of 3 501 iAAAs, including 1 124 (32.1%) OR and 2377 (67.9%) EVAR, and 409 rAAAs, including 218 (53.3%) OR and 191 (46.7%) EVAR, were identified. After centralisation, there was a significant decrease in overall mortality in iAAA repair (4.7% vs. 2.0%, p < .001) and rAAA repair (53.1% vs. 41.9%, p = .028). Mortality reduction in iAAAs was significant for OR (8.7% vs. 3.6%, p = .005), but not for EVAR (2.2% vs. 1.5%, p = .25). Overall LOS decreased as well, mainly in iAAAs (9.49 ± 10.84 vs. 7.44 ± 12.23 days, p < .001), and in particular in elective EVAR (7.32 ± 7.73 vs. 6.00 ± 8.97 days, p < .001). Multivariable analysis was identified before the centralisation period as an independent predictor for both mortality (odds ratio 1.484, 95% CI 1.098-2.005, p = .010) and LOS (B coefficient 1.146, 95% CI 0.218-2.073, p = .016). The implementation of a country based centralisation programme for AAA treatment led to a significant reduction in short term mortality, for both iAAA and rAAA, and mainly for elective OR. LOS also significantly decreased, mainly for elective EVAR. These results support the benefit of centralisation of AAA repair procedures.

Identifiants

pubmed: 32312668
pii: S1078-5884(20)30237-9
doi: 10.1016/j.ejvs.2020.03.009
pii:
doi:

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

531-538

Investigateurs

Albert Clarà (A)
Jaume Dilme (J)
Antonio Gimenez-Gaibar (A)
Oscar Pastor (O)
Ramon Vila (R)
Alejandro Guarga (A)
Maria J Pueyo-Sánchez (MJ)
Alfonso Pozuelo (A)
Cristina Casanovas-Guitart (C)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 European Society for Vascular Surgery. Published by Elsevier B.V. All rights reserved.

Auteurs

Paolo Tripodi (P)

Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain. Electronic address: https://twitter.com/PaoloTripodi8.

Gaspar Mestres (G)

Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.

Vicente Riambau (V)

Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.
Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH